Financial Reports Latest Updates Industry Maps Economic Calendar

Q32 Bio Inc. (QTTB) Annual Reports

Q: Where can I read Q32 Bio Inc. (QTTB) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Q32 Bio Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1661998 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Operating income	$-9.1M	$-9.2M	+0.6%
Net income	$-8.9M	$-9.5M	+5.7%
EPS (diluted)	$-0.44	$-0.78	+43.6%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 53.7 mn Net income -8.95 mn

Show table：Income statement

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	1.13	0.93	0.95	2.62	0.27	0.39	0.44	0.56	0.59	0.57	0.57	0.98	29.3	2.19	1.68	0.8	0.8	0.8	0.8	0.8	0.8	0.35	0	0	0	0	0	0	—	—	—	53.7	—	—
Operating income	-4.69	-6.04	-6.66	-12.3	-11.0	-13.9	-16.3	-20.4	-25.1	-28.0	-31.3	-25.6	-36.5	-35.7	-28.3	-29.8	-1.11	-30.6	-30.7	-33.6	-37.6	-28.3	-32.9	-34.5	-27.5	-30.8	-31.0	-12.1	-14.8	-17.9	-18.8	-14.5	-12.2	-9.17	-7.58	45.9	-7.72	-9.12
Net income	-5.55	-6.00	-6.53	-11.9	-10.5	-12.9	-14.8	-19.0	-23.9	-26.3	-29.6	-24.2	-35.3	-35.3	-28.2	-29.8	-1.07	-30.5	-30.6	-33.6	92.1	-29.1	-33.7	-34.3	-28.8	-35.0	-33.0	-16.1	1.03	-17.0	-17.6	-14.2	-11.0	-9.49	-7.39	57.7	-7.61	-8.95

Balance sheet

Quarterly · In mn (USD)

Total assets 116 mn Total liabilities 9.96 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	132	120	262	246	222	191	299	274	267	238	210	181	220	192	218	192	192	262	238	213	181	154	131	107	83.9	138	112	93.9	81.9	68.6	58.3	50.8	55.0	57.2	110
Total assets	—	—	—	138	129	270	268	259	233	341	317	311	289	258	228	264	235	259	231	212	311	285	263	228	198	169	140	84.6	152	124	105	92.3	79.1	66.1	57.8	61.8	63.7	116
Current liabilities	—	—	—	8.86	9.44	10.9	18.6	25.4	17.6	15.5	18.7	12.4	17.4	19.6	17.2	22.7	17.8	19.5	18.7	17.2	20.8	20.7	25.3	22.6	18.5	22.9	25.3	11.6	33.0	17.2	14.4	16.5	14.6	11.5	11.1	11.3	10.7	5.40
Total liabilities	—	—	—	39.2	40.8	43.5	55.6	64.4	58.8	56.4	58.9	52.1	62.3	63.5	58.1	67.7	33.9	34.3	32.2	42.1	44.7	44.3	53.6	50.5	46.0	50.0	51.9	11.6	104	90.7	86.3	86.7	83.1	78.3	76.2	19.8	17.4	9.96
Equity	—	—	—	-39.5	-49.5	227	213	195	174	285	258	259	227	195	170	196	201	225	199	170	266	240	209	178	152	119	88.2	73.0	48.8	33.5	18.3	5.68	-4.01	-12.2	-18.4	42.0	46.3	106

Cash flow

Quarterly · In mn (USD)

Operating -3.07 mn Investing 0 mn Financing 58.6 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-4.52	-5.60	-5.45	22.1	-11.0	-9.75	-13.7	-8.08	-17.9	-21.7	-25.5	-26.3	-25.9	-28.0	-28.9	-11.6	-29.8	-24.1	-25.4	-30.4	-30.7	-30.9	-24.9	-27.2	-26.1	-23.7	-24.9	-21.6	-14.6	-22.2	-19.5	-11.4	-12.5	-10.7	-4.23	-6.18	-6.34	-3.07
Investing	-0.85	-0.47	-0.3	-79.9	6.64	-93.4	-45.3	10.2	19.7	-38.3	-13.1	-20.0	115	52.0	38.8	-0.95	-85.2	-13.7	4.52	43.7	168	-41.4	-108	18.0	31.4	61.0	-22.8	31.7	0.1	9.89	9.94	0	0	0	0	7.00	0	0
Financing	20.5	0	83.1	11.7	-0.96	152	0.02	0.04	0.33	135	0.61	22.6	0.45	0.24	0.41	52.0	2.04	49.8	0.38	0	0.44	0	0.12	0.03	0.15	0	0.02	0.01	99.3	-5.52	1.00	0.32	—	0	-1.56	-1.56	8.80	58.6
Cash at period end	26.5	20.4	97.8	51.6	46.2	95.0	36.0	38.2	40.8	116	77.6	53.8	143	168	178	217	104	116	95.8	108	248	176	43.2	34.0	39.5	76.8	29.1	39.3	116	97.7	89.1	78.0	65.5	54.8	49.0	48.3	50.8	106

Profitability

Quarterly · %

Operating margin 85.4% Net margin 107.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	-974.5%	-1499.3%	-1706.5%	-778.7%	-9304.8%	-7136.0%	-7094.8%	-4539.8%	-6206.1%	-6295.8%	-4986.4%	-3041.0%	-3.8%	-1397.0%	-1828.3%	-4192.6%	-4690.5%	-3529.6%	-4097.5%	-4301.0%	-3430.3%	-8705.1%	—	—	—	—	—	—	—	—	—	85.4%	—	—
Net margin	—	—	—	—	-932.0%	-1391.8%	-1550.7%	-725.8%	-8834.1%	-6701.5%	-6718.1%	-4292.5%	-6008.7%	-6232.8%	-4979.2%	-3039.9%	-3.7%	-1394.6%	-1825.2%	-4187.4%	11484.4%	-3627.1%	-4205.2%	-4276.2%	-3596.5%	-9899.4%	—	—	—	—	—	—	—	—	—	107.4%	—	—

Returns & leverage

Quarterly · %

ROE 72.1% ROA 37.1% Debt ratio 8.6%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	-18.4%	-23.6%	-73.7%	-113.1%	-32.8%	-42.0%	-45.9%	-57.6%	-51.9%	-57.5%	-56.6%	-44.2%	-42.7%	-49.9%	-52.4%	-1.1%	-0.5%	-2.1%	-2.9%	-60.2%	-73.3%	-88.2%	-90.0%	-82.8%	-85.1%	-93.3%	-121.4%	-267.2%	-491.7%	—	125.1%	157.2%	72.1%
ROA	—	—	—	-21.8%	-27.1%	-15.5%	-18.7%	-28.9%	-39.0%	-27.4%	-33.8%	-36.5%	-44.2%	-41.5%	-45.1%	-44.8%	-36.1%	-34.6%	-40.1%	-40.3%	-0.9%	-0.4%	-1.7%	-2.3%	-49.5%	-58.1%	-65.1%	-72.2%	-47.5%	-44.3%	-40.6%	-54.0%	-51.7%	-55.0%	-51.9%	38.7%	46.6%	37.1%
Debt ratio	—	—	—	28.5%	31.6%	16.1%	20.7%	24.9%	25.2%	16.5%	18.6%	16.8%	21.6%	24.6%	25.5%	25.7%	14.4%	13.3%	14.0%	19.9%	14.4%	15.6%	20.4%	22.1%	23.2%	29.5%	37.0%	13.7%	68.0%	73.0%	82.5%	93.8%	105.1%	118.5%	131.9%	32.0%	27.3%	8.6%

EPS

Quarterly · US$

EPS US$-0.44

Show table：EPS

Item	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.02	-0.54	-0.54	-0.59	1.59	-0.51	-0.59	-0.60	-0.50	-0.61	-0.57	-0.27	-6.33	-1.42	-1.46	-0.98	-0.90	-0.78	-0.60	4.71	-0.54	-0.44

Revenue & profit

Year-to-date · In mn (USD)

Revenue 0 mn Net income -16.6 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 116 mn Total liabilities 9.96 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -9.42 mn Investing 0 mn Financing 67.4 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -8774.1% Net margin -9771.7%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE 72.1% ROA 37.1% Debt ratio 8.6%

EPS

Year-to-date · US$

EPS US$-0.98

Revenue & profit

Annual · In mn (USD)

Revenue 0 mn Net income 29.8 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	5.63	1.67	2.70	34.0	3.21	1.16	0	—
Operating income	-29.7	-61.6	-110	-130	-96.0	-133	-101	-66.1	16.9
Net income	-30.0	-57.2	-104	-129	-95.8	-5.00	-113	-47.7	29.8

Balance sheet

Annual · In mn (USD)

Total assets 61.8 mn Total liabilities 19.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	132	222	267	220	192	181	83.9	81.9	55.0
Total assets	138	259	311	264	212	228	84.6	92.3	61.8
Current liabilities	8.86	25.4	12.4	22.7	17.2	22.6	11.6	16.5	11.3
Total liabilities	39.2	64.4	52.1	67.7	42.1	50.5	11.6	86.7	19.8
Equity	-39.5	195	259	196	170	178	73.0	5.68	42.0

Cash flow

Annual · In mn (USD)

Operating -33.5 mn Investing 7.00 mn Financing 95.1 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	6.48	-42.6	-91.4	-94.3	-110	-114	-96.2	-67.7	-33.5
Investing	-81.5	-122	-51.8	205	-50.8	36.7	101	19.9	7.00
Financing	115	151	158	53.1	52.2	0.6	0.18	95.1	—
Cash at period end	51.6	38.2	53.8	217	108	34.0	39.3	78.0	48.3

Profitability

Annual · %

Operating margin -8774.1% Net margin -9771.7%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	-1094.0%	-6599.2%	-4821.0%	-282.4%	-4154.6%	-8774.1%	—	—
Net margin	—	-1016.7%	-6237.4%	-4762.9%	-281.9%	-156.0%	-9771.7%	—	—

Returns & leverage

Annual · %

ROE 125.1% ROA 38.7% Debt ratio 32.0%

Show table：Returns & leverage

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-73.7%	-45.9%	-56.6%	-52.4%	-2.9%	-90.0%	-121.4%	125.1%
ROA	-21.8%	-28.9%	-36.5%	-44.8%	-40.3%	-2.3%	-72.2%	-54.0%	38.7%
Debt ratio	28.5%	24.9%	16.8%	25.7%	19.9%	22.1%	13.7%	93.8%	32.0%

EPS

Annual · US$

EPS US$2.43

Show table：EPS

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	-1.69	-0.11	-1.95	-10.19	2.43

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Q32 Bio Inc. (QTTB) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.